Recently, Norroy Bioscience Co., Ltd. A-round of financing signing ceremony was held in Wuxi, Xinghua Dingli founder Mr. Wu Yuding and CEO of Norroy Mr. Yan Chenglong signed on behalf of the two sides.
This round of tens of millions of financing is exclusively invested by the old shareholder Xinghua Dingli, and the funds raised will be used to promote the development of the pre-clinical and clinical stage projects, and accelerate the promotion of domestic original research and innovative nuclear drugs in the global market.
Founded in 2021, Norroy bioscience Co., Ltd. is a biomedical enterprise dedicated to pioneering research and innovative diagnosis and treatment in the field of radio pharmaceuticals. Norroy's focused approach on addressing unmet clinical needs in urinary system tumors and gastrointestinal tumors has driven a fast proof of concept and rapid commercialization of our two-wheeled strategy. This strategic development aligns with China's original layout research innovation in nuclear medicine, emphasizing excellence in both the First Class and Best in Class dimensions.
Recently, Norroy has submitted an IND application for kidney cancer to FDA, and the application has been officially accepted. Norroy has successfully established a R&D team composed of nearly 70 top experts at home and abroad, and its own radioactive GMP facilities have been commissioned and fully put into use.
Mr. Wu, founder of Xinghua Dingli, said: New nuclear drugs have shown their great clinical value in the world, and will undoubtedly be an important way to diagnose and treat human diseases.
Norroy has built a complete industry senior team, firmly independent research and development, clinical data to speak, will continue to declare several innovative varieties.
86-0510-88786189
